Composition for inducing cell reprogramming
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 8, 2020
Grant Date -
Jun 8, 2017
app pub date -
Jun 30, 2015
filing date -
Jul 1, 2014
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to a composition for inducing cell reprogramming. The indazole derivative compound contained in the composition of the present invention shows an improved biological profile and at the same time can perform efficient cell reprogramming. In addition, unlike conventional compounds (e.g. riversine or BIO) for inducing low-molecular cell reprogramming, the indazole derivative compound of the present invention does not show cytotoxicity and thus is expected to have high growth in the market of cell therapy products when clinically applied. Conventional indazole derivative compounds have never known as a use for cell reprogramming. Compared with conventional indazole derivative compounds, the compound of the present invention has a great cell reprogramming ability while having no or little cytotoxicity.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully